Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 49Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 17Fallopian Tube Neoplasms 17Esophageal Squamous Cell Carcinoma 15Esophageal Neoplasms 15Neoplasms 14Neoplasm Metastasis 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Uterine Cervical Neoplasms 12Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Colorectal Neoplasms 6Carcinoma 6Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Peritoneal Neoplasms 3

Interventions

zaleplon 1olaparib 1Rehabilitation 1Psychotherapy 1Paclitaxel 1Oxaliplatin 1Olanzapine 1Nivolumab 1Niacin 1Injections 1Health Services Needs and Demand 1Gemcitabine 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Cancer × Paclitaxel × Clear all
NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

Phase 1/2 Recruiting
320 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡